MARKET

PLX

PLX

Protalix Biother
AMEX
1.590
+0.040
+2.58%
Pre Market: 1.590 0 0.00% 05:26 12/07 EST
OPEN
1.550
PREV CLOSE
1.550
HIGH
1.610
LOW
1.540
VOLUME
10
TURNOVER
0
52 WEEK HIGH
3.550
52 WEEK LOW
1.130
MARKET CAP
115.99M
P/E (TTM)
20.08
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PLX last week (1127-1201)?
Weekly Report · 3d ago
Weekly Report: what happened at PLX last week (1120-1124)?
Weekly Report · 11/27 11:31
Weekly Report: what happened at PLX last week (1113-1117)?
Weekly Report · 11/20 11:28
Protalix BioTherapeutics: Fiscal Challenges And Gout Therapy Prospects
Prox-115, in phase i trials for refractory gout, is crucial in a competitive market with high efficacy and safety standards. Protalix shows mixed financials with declining revenue, yet improved operating loss. Significant share dilution and debt raise long-term sustainability concerns.
Seeking Alpha · 11/17 21:16
Protalix’s Regulatory Success and Promising Pipeline Drive Buy Rating: An Analysis of Potential Profitability and Growth
Analyst ram selvaraju from h.c. Wainwright has a buy rating and a 12-month price target of $10.00 for protalix (plx) the company's lead product candidate elfabrio received approval in the u.s. And eu in may.
TipRanks · 11/14 11:33
Weekly Report: what happened at PLX last week (1106-1110)?
Weekly Report · 11/13 11:21
American Well, Protalix BioTherapeutics among healthcare movers
Organigram ogi, msp recovery, protalix biotherapeutics among healthcare movers. s&p 500 health care sector adds 0.13% to 1486.15. american well, american well and acurx pharmaceuticals among healthcare sector losers.
Seeking Alpha · 11/06 15:01
Earnings Scheduled For November 6, 2023
Benzinga · 11/06 13:24
More
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Its ProCellEx platform is being used to manufacture approved and marketed product, Elelyso, for the treatment of Gaucher disease. The Company’s ProCellEx is its proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. Protalix’s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target pharmaceutical markets, including the product candidates, such as PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases, and others.

Webull offers Protalix Biotherapeutics Inc stock information, including AMEX: PLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLX stock methods without spending real money on the virtual paper trading platform.